Malformations, Withdrawal Manifestations, and Hypoglycaemia After Exposure to Valproate in Utero

Total Page:16

File Type:pdf, Size:1020Kb

Malformations, Withdrawal Manifestations, and Hypoglycaemia After Exposure to Valproate in Utero 288 Archives of Disease in Childhood 1993; 69: 288-291 Malformations, withdrawal manifestations, and hypoglycaemia after exposure to valproate in utero E Thisted, F Ebbesen Abstract that there is an association between valproate An unselected series is presented of 17 treatment during pregnancy and spina bifida in infants born to epileptic mothers and the fetus.5 6 12 Furthermore, some authors exposed to sodium valproate during have postulated the existence of a 'fetal pregnancy. Nine infants had minor abnor- valproate syndrome', in which infants have malities and of these infants five also had minor abnormalities and major malformations major malformations, described as the to a variable degree.9 14 15 18 'fetal valproate syndrome'. The most We present 17 infants born to 17 epileptic frequent malformation was congenital mothers who received sodium valproate as heart disease. Nine of the infants had monotherapy or polytherapy during pregnancy. manifestations of withdrawal, such as The purpose ofthis study is to draw attention to irritability, jitteriness, abnormalities of the high frequency of minor abnormalities and tone, seizures, and feeding problems. major malformations, the withdrawal mani- Four of these infants had an unrelated festations, and hypoglycaemia in these infants. hypoglycaemia. The frequency of with- drawal symptoms was significantly related to the dose of valproate given to Patients and methods the mothers in the third trimester, and We studied all infants born to epileptic mothers there was a tendency for both the fre- treated with valproate as monotherapy or poly- quency of the minor abnormalities and therapy during pregnancy in the North Jutland the major malformations to be related to region of Denmark between 1 January 1987 the valproate dosage in the first trimester. and 31 December 1989. During this period (Arch Dis Child 1993; 69: 288-291) 18 000 infants were born. Seventeen mothers gave birth to 17 infants. Twelve mothers had primary generalised The frequency of minor abnormalities and epilepsy and five complex partial epilepsy major malformations in infants of epileptic (table 1). Eleven mothers had valproate as mothers is increased and associated with the monotherapy, three had valproate and carba- Department of epilepsy.' In addition, phenytoin given to mazepine, two valproate and ethosuximide, Paediatrics, Aalborg pregnant women might increase the frequency and one valproate and primidone (table 1). Hospital, Denmark of abnormalities and malformations, 'the Pregnant epileptic women were seen monthly E Thisted F Ebbesen fetal hydantoin syndrome'.2 Other antiepilep- by a neurologist. The drug plasma concen- tic drugs are suspected of having a teratogenic trations were measured and future doses Correspondence to: Dr Ebbe Thisted, effect. prescribed. Doses were titrated from pre- Department of Paediatrics, The teratogenic effect of valproate was pregnancy plasma concentrations to maintain University Hospital of Hvidovre, Kettegards Alle observed in animals by Pinder et al,3 and a a constant valproate concentration and to 30, DK-2650 Denmark. possible teratogenic effect has also been ensure, as far as possible, absence of seizures. Accepted 29 April 1993 described in humans.4-18 It has been suggested Concentrations were measured as fasting Table I Maternal data Epileptic Daily dose ofantiepileptic drug(s) in g/24 hours attack (range ofplasma concentrations in itmol/l) Mother Type of during Poor No epilepsy pregnancy Medication 1st trinester 2nd tnimester 3rd tnimester conmpliance Complex partial Valproate 0.0 0-6 '0 9 (266-360) 0-9 (326-347 2 Primary generalised Valproate 0 9 (159) 1-2 (232-271) 1-2 (256-338) 3 Primary generalised Valproate 0-9 (289) 0-9-1-2 (246-384) 1 2 (270-343) 4 Primary generalised Valproate 1 0 (467) 1 0 1 0 (67) + 5 Primary generalised Valproate 1 0 (123-361) 1-0 (157-238) 1 0 (154-200) 6 Primary generalised Valproate 1-2 1-2 (217) 1 2 (221-244) 7 Primary generalised Valproate 1-5 1-5- '2-5 (329-581) 2 5 '3-0 (351-426) 8 Primary generalised + Valproate 2-0 2-0 *2-5 (33-115) 3-0 (119-201) + 9 Complex partial Valproate 2-0 (550) 2-0-2-5 (252-513) 2 5 (301-373) 10 Complex partial Valproate 2-5 (498) 2-5-3-5 (495-821) 4 0-'50 (468-580) 11 Primary generalised Valproate 3-5 (792-1132) 3-5 (523-692) 3-5 (443-520) 12 Primary generalised Valproate, 1 0 (283-519) 1-5 -'2 0 (327-717) 2-0 (452-556) carbamazepine 0 4 -03 (22) 0-2 -'0-0 0.0 13 Complex partial Valproate, 1-0 (275) 1 0 (307-309) 1-5-2-0 (222-372) carbamazepine 0-8 (25) 0-8 (17-25) 1-2 '1 6 (18-19) 14 Complex partial + Valproate, 2-7 (249) 2-7 '3-3(216-290) 33-4-2 (141-481) + carbamazepine 0 8 (22-25) 12-'16 (17-20) 2 2 '3 2 (20-29) 15 Primary generalised Valproate, 3 0 (386) 3 6 -4-8 (372-468) 5-4-6-0 (383-599) + ethosuximide 1.0 1 0 (185-260) 1-0 (234-295) 16 Primary generalised Valproate, 4-8 (408) 5-4 -6-0 (256-476) 6-0 '6-6 (352-632) ethosuximide 1 0 (355) 1 0 (300-310) 1-0 (296-319) 17 Primary generalised Valproate, 2-5 (601-776) 30 '3 5 (674-1162) 3-5-'40 (385-1140) primidone 0 125 0 125 (5-10) 0 125 (3-6) Malformations, withdrawal manifestations, and hypoglycaemia after exposure to valproate in utero 289 Table 2 Infant data Hypoglycaemia Apgar Admitted (minimum Gestational Birth score to f blood Infant age weight 1-5 neonatal Hypertonial Feeding glucose No (weeks) (g) minutes unit Iritability _itteriness Hypertonia hypotonia Seizures problems (mmol/l)) 41 3250 10-10 + + + + 2 41 4000 10-10 3 42 4020 10-10 4 37 3150 10-10 + + 5 39 2500 10-10 6 39 3640 10-10 7 40 2950 6-10 + + + + 8 42 3300 10-10 9 39 3500 8-10 + + + + + 10 39 3125 6-9 + + + + + 06 11 38 3500 6-7 + 12 38 3900 10-10 13 42 4100 9-10 + + + + + 14 40 4040 10-10 + + + + 1-1 15 39 2760 10-10 + + + + 1-7 16 42 4300 10-10 + + + + + 17 40 2840 10-10 + + + + + 1-5 values at 8-10 am; valproate, carbamazepine, Results and ethosuxcimide were measured using the Mothers' data are given in table 1. The daily fluorescence polarisation immunoassay'9 and valproate dose varied from 0 0 g to 4-8 g in the primidone cooncentration was measured using first trimester and from 0-9 to 6-6 g in the third high pressur(e liquid chromatography.20 trimester. In 13 (78%) women the valproate All womera were offered amniocentesis but it dose needed to be increased during pregnancy was performled in only eight cases. Concen- to maintain a constant plasma valproate tration of x fetoprotein in amniotic fluid concentration. This concentration measured was normal as were fetal chromosomes. No between zero and 1162 ,umol/l. Four mothers therapeutic aibortion was performed. showed poor compliance and three of them The womren totally abstained from or used had epileptic attack(s) during pregnancy. only small aamounts of alcohol during preg- Data ofthe infants are given in table 2. Their nancy. gestational ages and birth weights were Eleven of the 17 infants (65%) were admit- normal, 40 (37-42) weeks and 3500 ted to the neonatal unit and subsequently (2500-4300) g (range), respectively. The followed up in the paediatric outpatient clinic. deliveries were uncomplicated and in no case The remainiing six infants were examined in was an infant significantly asphyxiated. the maternity ward by a paediatrician. These Eleven infants (65%) were admitted to the children wer^e investigated in the clinic at the neonatal unit in the first two days of life, nine age of 1-5-3-5 years. All infants were examined because of neurological symptoms and two using the rnotor perceptual developmental because of major malformations. test,2' and olbservations made of the children's Nine of the infants (53%) had minor abnor- ability in coracentrating, mimicry, and speech. malities (table 3), such as rough curly hair, Statistical analysis was performed using the epicanthic folds, hypertelorism, a deep groove X2 test. The 1level of significance was chosen at below the lower lids, upturned nose, ante- 5%. verted nostrils, shallow philtrum, thin upper vermillion border, low set or unusually shaped ears, overlapping toes, and inguinal hernias. Table 3 Minor abnormalities Major malformations were demonstrated in five of the nine infants with minor abnormali- Infant no ties (29% of the total; table 4). The most com- 4 7 10 11 13 15 16 17 mon malformation was a congenital heart -- defect, which was present in four. Rough curly hair + Epicanthic folds + + + + + + In those cases where the mothers received a Hypertelorism + + + + + + daily valproate dose of -2-5 g, five out of six Deep groove below the lower lids + Upturned nose + + + + + + infants were born with minor abnormalities; Anteverted nostrils + + + additionally three of the infants had major Shallow philtrum + + Thin upper vermillion border + + + + malformations. In those cases where the Low set or unusually shaped ears + + + + + mothers received less than 2 5 g valproate, only Overlapping toes Inguinal hernias + + + four out of 11 infants had minor abnormalities with additional major malformations in two. Table 4 Major malformations Infant No Malformations 4 Congenital heart defect (atrial septal defect and ventricular septal defect), radial deviation of the right hand 10 Congenital heart defect (pulmonary stenosis), bilateral cataract with suspicion of blindness, severe hearing defect 11 Congenital heart defect (Fallot's tetralogy), cheilognathopalatoschisis, perineoscrotal hypospadias, bilateral undescended testes 13 Congenital heart defect (bicuspid aortic valve with mild aortic insufficiency) 17 Severe herniation of oesophagus 290 Thisted, Ebbesen Nine (53%) of the infants developed neuro- plasma valproate during pregnancy.
Recommended publications
  • United States July 2016 2 Table of Contents
    Deuterium Labelled Compounds United States July 2016 2 Table of Contents International Distributors 3 Corporate Overview 4 General Information 5 Pricing and Payment 5 Quotations 5 Custom Synthesis 5 Shipping 5 Quality Control 6 Quotations 6 Custom Synthesis 6 Shipping 6 Quality Control 6 Chemical Abstract Service Numbers 6 Handling Hazardous Compounds 6 Our Products are Not Intended for Use in Humans 7 Limited Warranty 7 Packaging Information 7 Alphabetical Listings 8 Stock Clearance 236 Products by Category 242 n-Alkanes 243 α-Amino Acids, N-Acyl α-Amino Acids, N-t-BOC Protected α-Amino Acid 243 and N-FMOC Protected α-Amino Acids Buffers and Reagents for NMR Studies 245 Detergents 245 Environmental Standards 246 Fatty Acids and Fatty Acid Esters 249 Flavours and Fragrances 250 Gases 253 Medical Research Products 254 Nucleic Acid Bases and Nucleosides 255 Pesticides and Pesticide Metabolites 256 Pharmaceutical Standards 257 Polyaromatic Hydrocarbons (PAHs), Alkyl-PAHs, Amino-PAHs, 260 Hydroxy-PAHs and Nitro-PAHs Polychlorinated Biphenyls (PCBs) 260 Spin Labels 261 Steroids 261 3 International Distributors C Beijng Zhenxiang H EQ Laboratories GmbH Australia K Technology Company Graf-von-Seyssel-Str. 10 Rm. 15A01, Changyin Bld. 86199 Augsburg Austria H No. 88, YongDingLu Rd. Germany Beijing 100039 Tel.: (49) 821 71058246 Belgium J China Fax: (49) 821 71058247 Tel.: (86) 10-58896805 [email protected] China C Fax: (86) 10-58896158 www.eqlabs.de Czech Republic H [email protected] Germany, Austria, China Czech Republic, Greece, Denmark I Hungary,
    [Show full text]
  • Campro Catalog Stable Isotope
    Introduction & Welcome Dear Valued Customer, We are pleased to present to you our Stable Isotopes Catalog which contains more than three thousand (3000) high quality labeled compounds. You will find new additions that are beneficial for your research. Campro Scientific is proud to work together with Isotec, Inc. for the distribution and marketing of their stable isotopes. We have been working with Isotec for more than twenty years and know that their products meet the highest standard. Campro Scientific was founded in 1981 and we provide services to some of the most prestigious universities, research institutes and laboratories throughout Europe. We are a research-oriented company specialized in supporting the requirements of the scientific community. We are the exclusive distributor of some of the world’s leading producers of research chemicals, radioisotopes, stable isotopes and environmental standards. We understand the requirements of our customers, and work every day to fulfill them. In working with us you are guaranteed to receive: - Excellent customer service - High quality products - Dependable service - Efficient distribution The highly educated staff at Campro’s headquarters and sales office is ready to assist you with your questions and product requirements. Feel free to call us at any time. Sincerely, Dr. Ahmad Rajabi General Manager 180/280 = unlabeled 185/285 = 15N labeled 181/281 = double labeled (13C+15N, 13C+D, 15N+18O etc.) 186/286 = 12C labeled 182/282 = d labeled 187/287 = 17O labeled 183/283 = 13C labeleld 188/288 = 18O labeled 184/284 = 16O labeled, 14N labeled 189/289 = Noble Gases Table of Contents Ordering Information.................................................................................................. page 4 - 5 Packaging Information ..............................................................................................
    [Show full text]
  • Hypothalamic Principles Necessary for the Release of Ovulating Hormone from the Adenohypophysis
    EFFECT OF AMINOGLUTETHIMIDE ON REPRODUCTIVE PROCESSES IN FEMALE RATS W. J. EVERSOLE and D. J. THOMPSON Department of Life Sciences, Indiana State University, Terre Haute, Indiana 47809, U.S.A. (Received "òlst January 1974) Summary. Adult female rats injected subcutaneously with 100 mg aminoglutethimide phosphate (AGP)/kg/day for 4 weeks failed to become pregnant when placed in cohabitation with males during the last 2 weeks of the injection period. Lower doses depressed the fertility rate and reduced the litter size: the average litter size of three of eleven rats given 50 mg/kg/day was 4\m=.\7 young and of four of eleven rats given 25 mg was 7\m=.\0 young. Twenty-nine controls averaged 10\m=.\1/litter. Doses of 100 mg AGP/kg/day stopped vaginal cycling, prevented ovulation in adults, and delayed dissolution of the vaginal membrane in pubertal rats. Histological studies of the ovaries from rats with initial ages of 17 or 21 days which were injected with 25 to 100 mg AGP/kg/day for 2 weeks showed an increase in the number and size of vesicular follicles. Treatment of 27-day-old rats with 25 mg/kg/day for 2 weeks reduced the number of CL and three of four rats given 50 mg had ovaries lacking such bodies; all control ovaries in this group contained CL. These findings are taken as evidence that AGP inhibits ovulation but does not prevent follicular maturation. INTRODUCTION Many pharmacological compounds originally developed as anaesthetics, tranquillizers and anticonvulsants modify endocrine structures and functions (see Gaunt, Chart & Renzi, 1965).
    [Show full text]
  • Mechanisms of Action of Antiepileptic Drugs
    Review Mechanisms of action of antiepileptic drugs Epilepsy affects up to 1% of the general population and causes substantial disability. The management of seizures in patients with epilepsy relies heavily on antiepileptic drugs (AEDs). Phenobarbital, phenytoin, carbamazepine and valproic acid have been the primary medications used to treat epilepsy for several decades. Since 1993 several AEDs have been approved by the US FDA for use in epilepsy. The choice of the AED is based primarily on the seizure type, spectrum of clinical activity, side effect profile and patient characteristics such as age, comorbidities and concurrent medical treatments. Those AEDs with broad- spectrum activity are often found to exert an action at more than one molecular target. This article will review the proposed mechanisms of action of marketed AEDs in the US and discuss the future of AEDs in development. 1 KEYWORDS: AEDs anticonvulsant drugs antiepileptic drugs epilepsy Aaron M Cook mechanism of action seizures & Meriem K Bensalem-Owen† The therapeutic armamentarium for the treat- patients with refractory seizures. The aim of this 1UK HealthCare, 800 Rose St. H-109, ment of seizures has broadened significantly article is to discuss the past, present and future of Lexington, KY 40536-0293, USA †Author for correspondence: over the past decade [1]. Many of the newer AED pharmacology and mechanisms of action. College of Medicine, Department of anti epileptic drugs (AEDs) have clinical advan- Neurology, University of Kentucky, 800 Rose Street, Room L-455, tages over older, so-called ‘first-generation’ First-generation AEDs Lexington, KY 40536, USA AEDs in that they are more predictable in their Broadly, the mechanisms of action of AEDs can Tel.: +1 859 323 0229 Fax: +1 859 323 5943 dose–response profile and typically are associ- be categorized by their effects on the neuronal [email protected] ated with less drug–drug interactions.
    [Show full text]
  • Stems for Nonproprietary Drug Names
    USAN STEM LIST STEM DEFINITION EXAMPLES -abine (see -arabine, -citabine) -ac anti-inflammatory agents (acetic acid derivatives) bromfenac dexpemedolac -acetam (see -racetam) -adol or analgesics (mixed opiate receptor agonists/ tazadolene -adol- antagonists) spiradolene levonantradol -adox antibacterials (quinoline dioxide derivatives) carbadox -afenone antiarrhythmics (propafenone derivatives) alprafenone diprafenonex -afil PDE5 inhibitors tadalafil -aj- antiarrhythmics (ajmaline derivatives) lorajmine -aldrate antacid aluminum salts magaldrate -algron alpha1 - and alpha2 - adrenoreceptor agonists dabuzalgron -alol combined alpha and beta blockers labetalol medroxalol -amidis antimyloidotics tafamidis -amivir (see -vir) -ampa ionotropic non-NMDA glutamate receptors (AMPA and/or KA receptors) subgroup: -ampanel antagonists becampanel -ampator modulators forampator -anib angiogenesis inhibitors pegaptanib cediranib 1 subgroup: -siranib siRNA bevasiranib -andr- androgens nandrolone -anserin serotonin 5-HT2 receptor antagonists altanserin tropanserin adatanserin -antel anthelmintics (undefined group) carbantel subgroup: -quantel 2-deoxoparaherquamide A derivatives derquantel -antrone antineoplastics; anthraquinone derivatives pixantrone -apsel P-selectin antagonists torapsel -arabine antineoplastics (arabinofuranosyl derivatives) fazarabine fludarabine aril-, -aril, -aril- antiviral (arildone derivatives) pleconaril arildone fosarilate -arit antirheumatics (lobenzarit type) lobenzarit clobuzarit -arol anticoagulants (dicumarol type) dicumarol
    [Show full text]
  • Membrane Stabilizer Medications in the Treatment of Chronic Neuropathic Pain: a Comprehensive Review
    Current Pain and Headache Reports (2019) 23: 37 https://doi.org/10.1007/s11916-019-0774-0 OTHER PAIN (A KAYE AND N VADIVELU, SECTION EDITORS) Membrane Stabilizer Medications in the Treatment of Chronic Neuropathic Pain: a Comprehensive Review Omar Viswanath1,2,3 & Ivan Urits4 & Mark R. Jones4 & Jacqueline M. Peck5 & Justin Kochanski6 & Morgan Hasegawa6 & Best Anyama7 & Alan D. Kaye7 Published online: 1 May 2019 # Springer Science+Business Media, LLC, part of Springer Nature 2019 Abstract Purpose of Review Neuropathic pain is often debilitating, severely limiting the daily lives of patients who are affected. Typically, neuropathic pain is difficult to manage and, as a result, leads to progression into a chronic condition that is, in many instances, refractory to medical management. Recent Findings Gabapentinoids, belonging to the calcium channel blocking class of drugs, have shown good efficacy in the management of chronic pain and are thus commonly utilized as first-line therapy. Various sodium channel blocking drugs, belonging to the categories of anticonvulsants and local anesthetics, have demonstrated varying degrees of efficacy in the in the treatment of neurogenic pain. Summary Though there is limited medical literature as to efficacy of any one drug, individualized multimodal therapy can provide significant analgesia to patients with chronic neuropathic pain. Keywords Neuropathic pain . Chronic pain . Ion Channel blockers . Anticonvulsants . Membrane stabilizers Introduction Neuropathic pain, which is a result of nervous system injury or lives of patients who are affected. Frequently, it is difficult to dysfunction, is often debilitating, severely limiting the daily manage and as a result leads to the progression of a chronic condition that is, in many instances, refractory to medical This article is part of the Topical Collection on Other Pain management.
    [Show full text]
  • NACE Bromine Chemistry Review Paper
    25 YEARS OF BROMINE CHEMISTRY IN INDUSTRIAL WATER SYSTEMS: A REVIEW Christopher J. Nalepa Albemarle Corporation P.O. Box 14799 Baton Rouge, LA 70898 ABSTRACT Bromine chemistry is used to great advantage in nature for fouling control by a number of sessile marine organisms such as sponges, seaweeds, and bryozoans. Such organisms produce small quantities of brominated organic compounds that effectively help keep their surfaces clean of problem bacteria, fungi, and algae. For over two decades, bromine chemistry has been used to similar advantage in the treatment of industrial water systems. The past several years in particular has seen the development of several diverse bromine product forms – one-drum stabilized bromine liquids, all-bromine hydantoin solids, and pumpable gels. The purpose of this paper is to review the development of bromine chemistry in industrial water treatment, discuss characteristics of the new product forms, and speculate on future developments. Keywords: Oxidizing biocide, bleach, bromine, bromine chemistry, sodium hypobromite, activated sodium bromide, Bromochlorodimethylhydantoin, Bromochloromethyethylhydantoin, Dibromodi- methylhydantoin,, BCDMH, BCMEH, DBDMH, stabilized bromine chloride, stabilized hypobromite INTRODUCTION Sessile marine organisms generate metabolites to ward off predators and deter attachment of potential micro- and macrofoulants. Sponges, algae, and bryozoans for example, produce a rich variety of bromine-containing compounds that exhibit antifoulant properties (Fig. 1).1,2,3 Scientists are actively studying these organisms to understand how they maintain surfaces that are relatively clean and slime- free.4 Brominated furanones isolated from the red algae Delisea pulchra, for example, have been found to interfere with the chemical signals (acylated homoserine lactones) that bacteria use to communicate with one another to produce biofilms.5,6 This work may eventually lead to more effective control of microorganisms in a number of industries such as industrial water treatment, oil and gas production, health care, etc.
    [Show full text]
  • Vitamin D Receptor Promotes Healthy Microbial Metabolites
    www.nature.com/scientificreports OPEN Vitamin D receptor promotes healthy microbial metabolites and microbiome Ishita Chatterjee1, Rong Lu1, Yongguo Zhang1, Jilei Zhang1, Yang Dai 2, Yinglin Xia1 ✉ & Jun Sun 1 ✉ Microbiota derived metabolites act as chemical messengers that elicit a profound impact on host physiology. Vitamin D receptor (VDR) is a key genetic factor for shaping the host microbiome. However, it remains unclear how microbial metabolites are altered in the absence of VDR. We investigated metabolites from mice with tissue-specifc deletion of VDR in intestinal epithelial cells or myeloid cells. Conditional VDR deletion severely changed metabolites specifcally produced from carbohydrate, protein, lipid, and bile acid metabolism. Eighty-four out of 765 biochemicals were signifcantly altered due to the Vdr status, and 530 signifcant changes were due to the high-fat diet intervention. The impact of diet was more prominent due to loss of VDR as indicated by the diferences in metabolites generated from energy expenditure, tri-carboxylic acid cycle, tocopherol, polyamine metabolism, and bile acids. The efect of HFD was more pronounced in female mice after VDR deletion. Interestingly, the expression levels of farnesoid X receptor in liver and intestine were signifcantly increased after intestinal epithelial VDR deletion and were further increased by the high-fat diet. Our study highlights the gender diferences, tissue specifcity, and potential gut-liver-microbiome axis mediated by VDR that might trigger downstream metabolic disorders. Metabolites are the language between microbiome and host1. To understand how host factors modulate the microbiome and consequently alter molecular and physiological processes, we need to understand the metabo- lome — the collection of interacting metabolites from the microbiome and host.
    [Show full text]
  • Genetic Study of Congenital Heart Defects In
    8585 JMed Genet 1994;31:858-863 Genetic study of congenital heart defects in Northern Ireland (19741978) J Med Genet: first published as 10.1136/jmg.31.11.858 on 1 November 1994. Downloaded from E Jennifer Hanna, Norman C Nevin, John Nelson Abstract echocardiography, have been able to diagnose Congenital heart defects are a major con- lesions more accurately by non-invasive means. genital abnormality and are assuming The aim of this study, which allowed a follow increasing importance. A study was up period of 6 to 10 years (1979-1984), was to undertaken to estimate the incidence of obtain an accurate estimate of the incidence of congenital heart defects in Northern CHD in Northern Ireland. It included the total Ireland over a five year period (1974-1978), live- and stillbirth population over a five year to determine the age at diagnosis and to period (1974-1978) but unfortunately echocar- assess the risk of recurrence in sibs. An diography was not available for all patients incidence rate of 7-3 per 1000 total births during the period of study. was found. This reduced to 3-1 per 1000 Previous studies346"' 1-14 have shown a recur- total births if only invasive methods of rence risk in sibs varying from 1 4% to 3 4%. diagnosis (catheter studies, surgery, or To ascertain the recurrence risk in Northern necropsy) were considered. The overall Ireland, selected families identified by the risk of recurrence for sibs (excluding in- incidence study were examined in greater de- dex patients with chromosomal abnor- tail. In addition it was decided to look at the age malities and syndromes) was 3-1%.
    [Show full text]
  • Teratology Primer Birth Defects Research LOGY SO to C a IE R T
    Teratology Primer Birth Defects Research LOGY SO TO C A IE R T E Y T B Education i r h t c h r a de se fects re Prevention Authors Teratology Primer Sura Alwan F. Clarke Fraser Department of Medical Genetics Professor Emeritus of Human Genetics University of British Columbia McGill University Vancouver, BC V6H 3N1 Canada Montreal, QC H3A 1B1 Canada E-mail: [email protected] E-mail: [email protected] Steven B. Bleyl Jan M. Friedman Department of Pediatrics University of British Columbia University of Utah School of Medicine C.201 BCCH-Shoughnessy Site Salt Lake City, UT 84132-0001 USA 4500 Oak Street E-mail: [email protected] Vancouver, BC V6H 3N1 Canada E-mail: [email protected] Robert L. Brent Thomas Jefferson University Adriane Fugh-Berman Alfred I. duPont Hospital for Children Department of Physiology and Biophysics P.O. Box 269 Georgetown University Medical Center Wilmington, DE 19899 USA Box 571460 E-mail: [email protected] Washington, DC 20057-1460 USA E-mail: [email protected] Christina D. Chambers Departments of Pediatrics and Family and John M. Graham, Jr. Preventive Medicine Director of Clinical Genetics and Dysmorphology University of California at San Diego Cedars Sinai Medical Center School of Medicine 8700 Beverly Blvd., PACT Suite 400 9500 Gilman Dr., Mail Code 0828 Los Angeles, CA 90048 USA La Jolla, CA 92093-0828 USA E-mail: [email protected] E-mail: [email protected] Barbara F. Hales* George P. Daston Department Pharmacology and Therapeutics Procter & Gamble Company McGill University Miami Valley Laboratories 3655 Prom.
    [Show full text]
  • EUROCAT Syndrome Guide
    JRC - Central Registry european surveillance of congenital anomalies EUROCAT Syndrome Guide Definition and Coding of Syndromes Version July 2017 Revised in 2016 by Ingeborg Barisic, approved by the Coding & Classification Committee in 2017: Ester Garne, Diana Wellesley, David Tucker, Jorieke Bergman and Ingeborg Barisic Revised 2008 by Ingeborg Barisic, Helen Dolk and Ester Garne and discussed and approved by the Coding & Classification Committee 2008: Elisa Calzolari, Diana Wellesley, David Tucker, Ingeborg Barisic, Ester Garne The list of syndromes contained in the previous EUROCAT “Guide to the Coding of Eponyms and Syndromes” (Josephine Weatherall, 1979) was revised by Ingeborg Barisic, Helen Dolk, Ester Garne, Claude Stoll and Diana Wellesley at a meeting in London in November 2003. Approved by the members EUROCAT Coding & Classification Committee 2004: Ingeborg Barisic, Elisa Calzolari, Ester Garne, Annukka Ritvanen, Claude Stoll, Diana Wellesley 1 TABLE OF CONTENTS Introduction and Definitions 6 Coding Notes and Explanation of Guide 10 List of conditions to be coded in the syndrome field 13 List of conditions which should not be coded as syndromes 14 Syndromes – monogenic or unknown etiology Aarskog syndrome 18 Acrocephalopolysyndactyly (all types) 19 Alagille syndrome 20 Alport syndrome 21 Angelman syndrome 22 Aniridia-Wilms tumor syndrome, WAGR 23 Apert syndrome 24 Bardet-Biedl syndrome 25 Beckwith-Wiedemann syndrome (EMG syndrome) 26 Blepharophimosis-ptosis syndrome 28 Branchiootorenal syndrome (Melnick-Fraser syndrome) 29 CHARGE
    [Show full text]
  • Hypoplastic Left Heart Syndrome in a Patient with Fetal Hydantoin Syndrome
    eona f N tal l o B a io n l r o u g y o J Mumphrey et al., J Neonatal Biol 2016, 5:2 Journal of Neonatal Biology DOI: 10.4172/2167-0897.1000217 ISSN: 2167-0897 Case Report Open access Hypoplastic Left Heart Syndrome in a Patient with Fetal Hydantoin Syndrome Christy G Mumphrey*1, Brian Barkemeyer1 and Regina M Zambrano2 1Department of Pediatrics, Division of Neonatology, Louisiana State University Health Sciences Center, New Orleans, Louisiana, USA 2Department of Pediatrics, Division of Genetics, Louisiana State University Health Sciences Center, New Orleans, Louisiana, USA *Corresponding author: Christy G. Mumphrey, Division of Neonatology, Louisiana State University Health Sciences Center, USA, Tel: +(504) 896-9418; E-mail: [email protected] Rec date: March 01, 2016; Acc date: April 29, 2016; Pub date: May 05, 2016 Copyright: © 2016 Mumphrey CG, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Abstract We report a patient with fetal hydantoin syndrome and hypoplastic left heart. Only three other cases with this association have been described. This case also highlights the importance genetic variation plays in the phenotypic variability of teratogens and the importance of good prenatal care to minimize risk of teratogenesis. Keywords: Fetal hydantoin syndrome; Hypoplastic left heart thumbs, a tendency to transverse palmar crease on both hands and syndrome; Dilantin embryopathy; Phenytoin embryopathy; Teratogen long toes with absent toenails (Figures 1-3). Echocardiogram showed mitral and aortic atresia with a diminutive left ventricle and ascending Introduction aorta, consistent with hypoplastic left heart.
    [Show full text]